Regeneron Pharmaceuticals, Inc. (REGN) To Go Ex-Dividend on May 20th

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced a quarterly dividend on Saturday, May 17th, Wall Street Journal reports. Shareholders of record on Tuesday, May 20th will be paid a dividend of 0.88 per share by the biopharmaceutical company on Friday, June 6th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.59%. The ex-dividend date is Tuesday, May 20th.

Regeneron Pharmaceuticals has a payout ratio of 8.9% indicating that its dividend is sufficiently covered by earnings. Analysts expect Regeneron Pharmaceuticals to earn $38.02 per share next year, which means the company should continue to be able to cover its $3.52 annual dividend with an expected future payout ratio of 9.3%.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $594.32 on Friday. The stock has a market cap of $64.17 billion, a PE ratio of 15.53, a P/E/G ratio of 2.34 and a beta of 0.43. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a twelve month low of $520.50 and a twelve month high of $1,211.20. The stock has a fifty day simple moving average of $599.96 and a 200-day simple moving average of $682.98.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion for the quarter, compared to analysts’ expectations of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business’s revenue for the quarter was down 3.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $9.55 earnings per share. Equities analysts anticipate that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of research analyst reports. The Goldman Sachs Group lowered their price target on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating for the company in a report on Wednesday, April 30th. Guggenheim lowered their target price on Regeneron Pharmaceuticals from $940.00 to $810.00 and set a “buy” rating for the company in a report on Thursday, May 1st. Canaccord Genuity Group upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, April 22nd. UBS Group lowered their target price on Regeneron Pharmaceuticals from $768.00 to $633.00 and set a “neutral” rating for the company in a report on Wednesday, April 30th. Finally, StockNews.com cut Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, May 1st. One analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have issued a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $890.60.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

An institutional investor recently raised its position in Regeneron Pharmaceuticals stock. Brighton Jones LLC boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 261.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 948 shares of the biopharmaceutical company’s stock after buying an additional 686 shares during the period. Brighton Jones LLC’s holdings in Regeneron Pharmaceuticals were worth $675,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.